The post RFK Jr. Is Targeting Vaccines And Tylenol. Are Prozac And Ozempic Next? appeared on BitcoinEthereumNews.com. Secretary of Health and Human Services Robert F. Kennedy Jr. The Associated Press Tylenol maker Kenvue is reeling after unsupported claims that its popular drug causes autism. Kennedy is unlikely to stop there. Tylenol may be only the beginning. For years, Robert F. Kennedy Jr. has railed against a number of medications and therapeutics claiming without scientific consensus or evidence that they cause some kind of harm — autism (Tylenol), suicidal thoughts (Ozempic). Now, as President Trump’s head of Health and Human Services, he’s begun turning his opinions into public policy. His Make American Healthy Again initiative has already made it harder for people to get vaccinated against COVID-19 and pushed unverified claims about Tylenol, and he’s just getting started. So what might be next? Kennedy’s already told us. On Monday, Kennedy and FDA Commissioner Marty Makary wrote in a letter to 22 Republican attorneys general that the FDA was reviewing evidence about the safety of abortion drug, mifepristone, which is used in nearly two-thirds of medical abortions. If access to the pill were restricted, it would significantly cut back on abortion access. Another big target: antidepressants. During Kennedy’s confirmation hearings, he falsely claimed that people have a harder time stopping the use of serotonin-based antidepressants “than people have getting off of heroin.” He’s also made the unfounded claim that teenagers who use them are more likely to commit school shootings (they aren’t.) One of the goals of Kennedy’s “Make America Healthy Again” movement is to “assess the prevalence of and threat posed by the prescription of selective serotonin reuptake inhibitors.” Any restrictions on them would be a grave concern to the approximately 11% of the population that uses them to treat depression, anxiety and other issues. Another frequent target of Kennedy’s are statins, which more than 92 million Americans… The post RFK Jr. Is Targeting Vaccines And Tylenol. Are Prozac And Ozempic Next? appeared on BitcoinEthereumNews.com. Secretary of Health and Human Services Robert F. Kennedy Jr. The Associated Press Tylenol maker Kenvue is reeling after unsupported claims that its popular drug causes autism. Kennedy is unlikely to stop there. Tylenol may be only the beginning. For years, Robert F. Kennedy Jr. has railed against a number of medications and therapeutics claiming without scientific consensus or evidence that they cause some kind of harm — autism (Tylenol), suicidal thoughts (Ozempic). Now, as President Trump’s head of Health and Human Services, he’s begun turning his opinions into public policy. His Make American Healthy Again initiative has already made it harder for people to get vaccinated against COVID-19 and pushed unverified claims about Tylenol, and he’s just getting started. So what might be next? Kennedy’s already told us. On Monday, Kennedy and FDA Commissioner Marty Makary wrote in a letter to 22 Republican attorneys general that the FDA was reviewing evidence about the safety of abortion drug, mifepristone, which is used in nearly two-thirds of medical abortions. If access to the pill were restricted, it would significantly cut back on abortion access. Another big target: antidepressants. During Kennedy’s confirmation hearings, he falsely claimed that people have a harder time stopping the use of serotonin-based antidepressants “than people have getting off of heroin.” He’s also made the unfounded claim that teenagers who use them are more likely to commit school shootings (they aren’t.) One of the goals of Kennedy’s “Make America Healthy Again” movement is to “assess the prevalence of and threat posed by the prescription of selective serotonin reuptake inhibitors.” Any restrictions on them would be a grave concern to the approximately 11% of the population that uses them to treat depression, anxiety and other issues. Another frequent target of Kennedy’s are statins, which more than 92 million Americans…

RFK Jr. Is Targeting Vaccines And Tylenol. Are Prozac And Ozempic Next?

2025/09/26 19:16

Secretary of Health and Human Services Robert F. Kennedy Jr.

The Associated Press

Tylenol maker Kenvue is reeling after unsupported claims that its popular drug causes autism. Kennedy is unlikely to stop there.

Tylenol may be only the beginning.

For years, Robert F. Kennedy Jr. has railed against a number of medications and therapeutics claiming without scientific consensus or evidence that they cause some kind of harm — autism (Tylenol), suicidal thoughts (Ozempic). Now, as President Trump’s head of Health and Human Services, he’s begun turning his opinions into public policy. His Make American Healthy Again initiative has already made it harder for people to get vaccinated against COVID-19 and pushed unverified claims about Tylenol, and he’s just getting started. So what might be next? Kennedy’s already told us.

On Monday, Kennedy and FDA Commissioner Marty Makary wrote in a letter to 22 Republican attorneys general that the FDA was reviewing evidence about the safety of abortion drug, mifepristone, which is used in nearly two-thirds of medical abortions. If access to the pill were restricted, it would significantly cut back on abortion access.

Another big target: antidepressants. During Kennedy’s confirmation hearings, he falsely claimed that people have a harder time stopping the use of serotonin-based antidepressants “than people have getting off of heroin.” He’s also made the unfounded claim that teenagers who use them are more likely to commit school shootings (they aren’t.)

One of the goals of Kennedy’s “Make America Healthy Again” movement is to “assess the prevalence of and threat posed by the prescription of selective serotonin reuptake inhibitors.” Any restrictions on them would be a grave concern to the approximately 11% of the population that uses them to treat depression, anxiety and other issues.

Another frequent target of Kennedy’s are statins, which more than 92 million Americans take to prevent heart disease and lower cholesterol. Most studies find that statins are both safe and help to prevent serious heart disease, which is the number one killer of Americans.

Yet Children’s Health Defense, the organization Kennedy founded, has published articles questioning the relationship of cholesterol to heart disease, with one calling them “overprescribed and unnecessary.” And earlier this year, as HHS Secretary, Kennedy claimed on a podcast that pharmaceutical companies manipulated studies to show they work.

One of the rationales for the agency’s recent crackdown on pharmaceutical ads is increased uptake of the drugs. Statins were the drugs of an older generation. Also in the crosshairs are newer innovations, like the increasingly popular GLP-1s used to treat diabetes (Ozempic, Mounjaro) and obesity (Wegovy, Zepbound). These drugs have recently been approved for additional health problems, such as sleep apnea, and are even being investigated for drug addiction.

That remarkable success hasn’t stopped Kennedy from criticizing their cost (they are expensive) and making false claims about them. For example, he falsely said that Novo Nordisk, which makes Ozempic, doesn’t market it in Europe. (It does.) He’s also said that ensuring Americans eat a good diet would solve the obesity problem–but multiple clinical studies have shown that GLP-1s are vastly superior to diet alone to helping people not only lose weight but keep it off.

In a first jab at their use, Kennedy rejected a plan to have Medicare cover the cost of GLP-1 drugs for obesity, which would have given 7 million Americans access to them, in April. (Medicare already covers these treatments for diabetes.) Could more restrictions on their use be seen down the road?

“They’re counting on selling it to Americans because we’re so stupid and so addicted to drugs,” Kennedy told viewers of Fox News about Ozempic and its manufacturer Novo Nordisk.

It’s not clear what, if anything, would change his mind.

MORE FROM FORBES

ForbesTrump’s Unproven Claims About Tylenol And Autism Are Reaching Millions On TikTokForbesRFK Jr.’s CDC Is Poised To Restrict Vaccines Even FurtherForbesThis Startup Hit A $3.25 Billion Valuation Building Software To Fix Drug Pricing

Source: https://www.forbes.com/sites/alexknapp/2025/09/26/rfk-jr-is-targeting-vaccines-and-tylenol-are-prozac-and-ozempic-next/

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Share Insights

You May Also Like

Cathie Wood: Early Life and Net Worth – The Vision Behind ARK Invest and the Future of Innovation

Cathie Wood: Early Life and Net Worth – The Vision Behind ARK Invest and the Future of Innovation

Cathie Wood’s vision shapes the future of disruptive innovation investments. ARK Invest pioneers the future of technology through strategic investment leadership. Cathie Wood’s wealth reflects her bold bets on transformative technologies. Cathie Wood is revolutionizing the world of finance and investment with her bold approach to disruptive innovation. As the founder, CEO, and CIO of ARK Invest, Wood has become a prominent figure in the financial world, known for her unwavering belief in the transformative potential of groundbreaking technologies. Her work is reshaping how investors view sectors such as artificial intelligence (AI), robotics, electric vehicles, and genomics. Wood’s influence extends beyond managing one of the most influential investment firms in the world—she is helping to pioneer a new approach to investing, where innovation is at the core. Through ARK Invest, Wood is leading the way for investors to understand and capitalize on the opportunities presented by technological disruption. Also Read: Mike Novogratz: Early Life and Net Worth – The Vision Behind Galaxy Digital and the Future of Crypto Cathie Wood: Early Life and Career Cathie Wood was born in 1955 in Los Angeles, California. Growing up, she was always intellectually curious and driven. After earning a degree in economics from the University of Southern California, she began her career in the investment world. Early on, she joined Capital Group, where she honed her skills in asset management, before transitioning to other firms like Jennison Associates and AllianceBernstein, where she specialized in growth investing. Her time at these firms helped Wood develop her investment philosophy: a long-term, research-driven approach that focuses on identifying disruptive technologies that can change the world. By 2014, with years of experience under her belt, Wood decided to pursue her vision independently by founding ARK Invest. The Birth of ARK Invest: A New Era of Disruptive Innovation In 2014, Wood founded ARK Invest with the bold vision of building a firm that focused on investing in disruptive innovation. Unlike traditional investment firms, ARK Invest takes an active approach to identifying and investing in technologies that have the potential to change industries and societies. ARK’s unique approach involves significant research into emerging technologies and their long-term impact, enabling the firm to anticipate trends and build a diversified portfolio of future-focused assets. ARK Invest has become widely known for its ability to invest in and nurture companies that are leading the way in industries like electric vehicles, autonomous driving, gene editing, and artificial intelligence. Under Wood’s leadership, ARK Invest has made early investments in groundbreaking companies such as Tesla, Roku, Square, and CRISPR Therapeutics, becoming one of the most influential players in the world of technology investment. Wood’s belief in the power of innovation has been central to the firm’s success. She has made it her mission to uncover technological breakthroughs and support them by backing companies that are on the cutting edge of transformation. Through ARK Invest, Wood has helped investors realize the potential of disruptive technologies in shaping the future of industries. A Vision for the Future: Embracing Disruption Cathie Wood’s investment philosophy revolves around her belief that innovation is the key to unlocking the future. Her vision goes beyond short-term market trends and focuses on technologies that will shape the next generation of businesses and economies. According to Wood, the industries that seem the most unlikely today are often the ones with the most potential for disruptive change. Wood is a staunch advocate for investing in disruptive innovation across five key areas: artificial intelligence, energy storage, robotics, DNA sequencing, and blockchain technology. Her vision is rooted in the idea that these fields will redefine how we live, work, and interact with the world. Her firm’s strategies often involve taking concentrated positions in companies that are well-positioned to benefit from these trends. For Wood, investing in disruptive technologies isn’t just about profit—it’s about fostering positive societal change. She believes that advancements in AI and genomics, for instance, can unlock new opportunities for medical treatments, making healthcare more personalized and accessible to millions. Cathie Wood’s Net Worth: The Wealth Behind the Vision As of 2025, Cathie Wood’s estimated net worth is between $230 million and $250 million. This wealth comes primarily from her 50% ownership stake in ARK Invest and her personal investments in disruptive technologies, including a significant allocation to Bitcoin. These estimates reflect the volatility inherent in Wood’s investment strategy, which focuses on high-growth sectors like artificial intelligence, genomics, and blockchain. ARK Invest’s performance has experienced fluctuations, impacting her personal wealth accordingly. For example, Forbes reported a decline in her net worth to $140 million in 2022, down from $400 million in 2021, due to market downturns affecting ARK’s funds. It’s important to note that these figures are estimates, as Wood’s exact net worth is not publicly disclosed. However, her significant role in ARK Invest and her investments in emerging technologies position her as a prominent figure in the investment community. Legacy: A Pioneer of the Disruptive Innovation Movement Cathie Wood’s legacy will likely be defined by her pioneering approach to investment in disruptive innovation. She has positioned herself as a leader not just in the financial world, but also as a thought leader in technology and societal change. Wood has made a name for herself by identifying long-term trends that others overlook, embracing technologies that are still in their infancy and betting on their future potential. Through her leadership at ARK Invest, Wood has challenged traditional approaches to investing and has been a vocal advocate for long-term, forward-thinking strategies. Her firm’s focus on high-growth, high-risk companies has created a new blueprint for understanding innovation in the 21st century. She has inspired both individual and institutional investors to rethink how they approach risk and reward, encouraging them to look toward the future instead of focusing on the status quo. Wood’s commitment to supporting the growth of transformative companies has not only shaped the investment landscape but has also influenced how the world thinks about the future of technology and its societal implications. FAQs 1. Who is Cathie Wood? Cathie Wood is the founder, CEO, and CIO of ARK Invest, an investment management firm that focuses on disruptive innovation. She is known for her expertise in identifying emerging technologies and her bold investment strategies in industries like AI, robotics, and genomics. 2. What is ARK Invest? ARK Invest is a global investment firm founded by Cathie Wood in 2014. The firm focuses on disruptive innovation and invests in emerging technologies such as artificial intelligence, robotics, and blockchain. ARK Invest is known for its actively managed exchange-traded funds (ETFs) that focus on high-growth sectors. 3. What is Cathie Wood’s net worth? As of 2025, Cathie Wood’s estimated net worth is $6.5 billion, primarily derived from her investments in disruptive technologies and her ownership stake in ARK Invest. 4. What is Cathie Wood’s investment philosophy? Cathie Wood’s investment philosophy centers on identifying and investing in disruptive technologies that have the potential to transform industries and societies. She focuses on five key areas: artificial intelligence, energy storage, robotics, DNA sequencing, and blockchain. 5. How has Cathie Wood influenced the investment world? Cathie Wood has redefined how investors approach disruptive technologies, advocating for a long-term investment strategy that embraces high-growth, transformative companies. Her leadership at ARK Invest has made her a key figure in shaping the future of technology and finance. Also Read: Joe Lubin: Early Life and Net Worth – The Vision Behind Consensys and Ethereum The post Cathie Wood: Early Life and Net Worth – The Vision Behind ARK Invest and the Future of Innovation appeared first on 36Crypto.
Share
Coinstats2025/10/04 19:50
Share